These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 3021710)

  • 1. Antifungal effects of fluconazole (UK 49858), a new triazole antifungal, in vitro.
    Odds FC; Cheesman SL; Abbott AB
    J Antimicrob Chemother; 1986 Oct; 18(4):473-8. PubMed ID: 3021710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suppression of ATP in Candida albicans by imidazole and derivative antifungal agents.
    Odds FC; Cheesman SL; Abbott AB
    Sabouraudia; 1985 Dec; 23(6):415-24. PubMed ID: 3913012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro antifungal activity of posaconazole against various pathogenic fungi.
    Uchida K; Yokota N; Yamaguchi H
    Int J Antimicrob Agents; 2001 Aug; 18(2):167-72. PubMed ID: 11516940
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antifungal drug resistance in pathogenic fungi.
    Vanden Bossche H; Dromer F; Improvisi I; Lozano-Chiu M; Rex JH; Sanglard D
    Med Mycol; 1998; 36 Suppl 1():119-28. PubMed ID: 9988500
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [In vitro activity of fluconazole, a novel bistriazole antifungal agent].
    Yamaguchi H; Uchida K; Kawasaki K; Matsunaga T
    Jpn J Antibiot; 1989 Jan; 42(1):1-16. PubMed ID: 2540356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antifungal relative inhibition factors: BAY l-9139, bifonazole, butoconazole, isoconazole, itraconazole (R 51211), oxiconazole, Ro 14-4767/002, sulconazole, terconazole and vibunazole (BAY n-7133) compared in vitro with nine established antifungal agents.
    Odds FC; Webster CE; Abbott AB
    J Antimicrob Chemother; 1984 Aug; 14(2):105-14. PubMed ID: 6094418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Action of fluconazole (UK-49,858) in relation to other systemic antifungal azoles.
    Hughes CE; Beggs WH
    J Antimicrob Chemother; 1987 Feb; 19(2):171-4. PubMed ID: 3032882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antifungal activity of saperconazole (R 66 905) in vitro.
    Odds FC
    J Antimicrob Chemother; 1989 Oct; 24(4):533-7. PubMed ID: 2613602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Azole resistance in Candida albicans.
    Smith KJ; Warnock DW; Kennedy CT; Johnson EM; Hopwood V; Van Cutsem J; Vanden Bossche H
    J Med Vet Mycol; 1986 Apr; 24(2):133-44. PubMed ID: 3014106
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current advances of triazole alcohols derived from fluconazole: Design, in vitro and in silico studies.
    Emami S; Ghobadi E; Saednia S; Hashemi SM
    Eur J Med Chem; 2019 May; 170():173-194. PubMed ID: 30897396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis, and biological evaluation of novel 1, 2, 4-triazole derivatives as antifungal agent.
    Chai X; Yu S; Jiang Y; Zou Y; Wu Q; Zhang D; Jiang Y; Cao Y; Sun Q
    Arch Pharm Res; 2012 Nov; 35(11):1895-901. PubMed ID: 23212630
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activity of fluconazole on Candida albicans.
    Abecia LC; Arévalo JM; López MJ
    Microbiologia; 1996 Dec; 12(4):613-20. PubMed ID: 9018696
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of the new triazole, voriconazole (UK-109,496), on the interactions of Candida albicans and Candida krusei with endothelial cells.
    Fratti RA; Belanger PH; Sanati H; Ghannoum MA
    J Chemother; 1998 Feb; 10(1):7-16. PubMed ID: 9531069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro activity of voriconazole against yeasts, moulds and dermatophytes in comparison with fluconazole, amphotericin B and griseofulvin.
    Wildfeuer A; Seidl HP; Paule I; Haberreiter A
    Arzneimittelforschung; 1997 Nov; 47(11):1257-63. PubMed ID: 9428984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and biological evaluation of fluconazole analogs with triazole-modified scaffold as potent antifungal agents.
    Hashemi SM; Badali H; Irannejad H; Shokrzadeh M; Emami S
    Bioorg Med Chem; 2015 Apr; 23(7):1481-91. PubMed ID: 25740636
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel conformationally restricted triazole derivatives with potent antifungal activity.
    Wang W; Wang S; Liu Y; Dong G; Cao Y; Miao Z; Yao J; Zhang W; Sheng C
    Eur J Med Chem; 2010 Dec; 45(12):6020-6. PubMed ID: 20950895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resistance in human pathogenic yeasts and filamentous fungi: prevalence, underlying molecular mechanisms and link to the use of antifungals in humans and the environment.
    Jensen RH
    Dan Med J; 2016 Oct; 63(10):. PubMed ID: 27697142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of imidazole- and triazole-derivative antifungal compounds on the growth and morphological development of Candida albicans hyphae.
    Odds FC; Cockayne A; Hayward J; Abbott AB
    J Gen Microbiol; 1985 Oct; 131(10):2581-9. PubMed ID: 2999296
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of azole antifungals in vitro on host/parasite interactions relevant to Candida infections.
    Odds FC; Webster CE
    J Antimicrob Chemother; 1988 Oct; 22(4):473-81. PubMed ID: 2849601
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Synthesis and antifungal activity of 1-(1H-1,2,4-triazole-1-yl)-2-(2,4-difluorophenyl)-3-substituted-2-propanols].
    Zhang DZ; Zhou TS; Wu YJ; Liu CM; Ma MC; Feng XT
    Yao Xue Xue Bao; 1997 Dec; 32(12):943-9. PubMed ID: 11596195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.